BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses Among Transplant Recipients Who Had Received Two Doses of CoronaVac

Autor: Çiğdem Erol, Zeynep Ece Kuloğlu, Bircan Kayaaslan, Gülen Esken, Adalet Altınsoy, Tayfun Barlas, Güle Çınar, İmran Hasanoğlu, Ebru Oruç, Said İncir, Alpay Azap, Gülten Korkmaz, Dilara Turan Gökçe, Onur Elvan Kırımker, Ezgi Coşkun Yenigün, Erkan Ölçücüoğlu, Ebru Ayvazoğlu Soy, Süleyman Çetinkünar, Özlem Kurt Azap, Füsun Can, Mehmet Haberal
Rok vydání: 2022
Popis: Introduction: We evaluated neutralizing antibody and anti-spike antibody (anti-S) response against omicron variant in solid organ (SOT) or hematopoietic stem cell (HSTC) receivers after third dose of BNT162b2 (BNT) or CoronaVac (CV) following two doses of CV. Methods: In total, 95 participants who underwent SOT (n=62; 44 liver, 18 kidney) or HSCT (n=27; 5 allogeneic, 22 autologous) were included from five centers in Turkey. The median time between third doses and serum sampling was 154 days. The vaccine-induced antibody responses of both neutralizing antibodies and Anti-Spike antibodies were assessed by plaque neutralizing assay and immunoassay. Results: Neutralizing antibody and anti-spike IgG levels were significantly higher in transplant patients receiving BNT compared to those receiving CV (GMT:26.76 vs 10.89; p=0.03 and 2116 Au/ml vs 172.1 Au/ml; pConclusion: This study highlights the superiority of BNT responses against omicron as a third dose among transplant recipients after two doses of CV. Lack of neutralizing antibody against omicron after CV in liver transplant recipients should be taken into consideration particularly in countries where inactivated vaccines are available in addition to mRNA vaccines.
Databáze: OpenAIRE